StreetAlpha.app
Home › Stocks › TARS

Tarsus Pharmaceuticals, Inc. (TARS)

Healthcare
$78.20
▼ −0.61%
LAST CLOSE · NOV 17

Tarsus Pharmaceuticals develops and sells eye care treatments, including XDEMVY for an eyelid condition caused by mites. It last closed at $78.20 on Nov 17, down 0.61% on the day. TARS last reported earnings on Tue, Nov 3, 2026. The average 12-month price target from 5 analysts is $106.80 (+36.6% from the last close), with a high of $116.00 and a low of $97.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell).

AI Auto Pilots
Is TARS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$682.2M
+86.3% vs a year ago
Net income
−$702.2M
−102.9% margin
EPS (diluted)
−$15.86
Free cash flow
$32.4M
4.8% margin
Valuation
Market cap
$3.9B
49.3M shares
P/E
–
No P/E while losing money
Price to sales
5.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$136.5M
At Sep 30
Debt
$72.9M
At Sep 30
Shareholder equity
$104.0M
Shares outstanding
49.3M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $57.0M$57.0MFY2021FY2022: $25.8M$25.8MFY2022FY2023: $17.4M$17.4MFY2023FY2024: $183.0M$183.0MFY2024FY2025: $451.4M$451.4MFY2025

From TARS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Last report
Nov 3
2026 · After the close (AMC)
Reported EPS
-$0.78
vs -$1.43 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±12.7%
Priced in before that report
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
5 Buy0 Hold0 Sell
Each firm's latest rating on TARS in the past 90 days
Average 12-month target
$106.80
▲ 36.6% upside

Based on 5 analysts who set a price target on TARS in the past 90 days. The average target is $106.80, with a high of $116.00 and a low of $97.00, compared with the last close of $78.20.

Low $97.00Avg $106.80High $116.00
Blue marker: last close $78.20
Highest target$116.00
Average target$106.80
Lowest target$97.00
Latest rating changes
GuggenheimMaintained
Nov 5Buy$97
HC Wainwright & Co.Maintained
Nov 4Buy$106
Goldman SachsReinstated
Sep 24Buy$116
BarclaysReinstated
Sep 16Buy$110
JefferiesMaintained
Sep 8Buy$105
DateFirmActionRatingPrice target
Nov 5GuggenheimMaintainedBuy$97
Nov 4HC Wainwright & Co.MaintainedBuy$106
Sep 24Goldman SachsReinstatedBuy$116
Sep 16BarclaysReinstatedBuy$110
Sep 8JefferiesMaintainedBuy$105
Loading…

Technical Analysis

TARS · as of the Nov 17 close · updated after every close
Uptrend

The stock is 7% above its 20 day and 5% above its 50 day average. It is 13% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 60). The nearest support is the Pivot at $77.63, and the nearest resistance the Pivot R1 at $78.96.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 4.7%/day
Key levels
$91.5352 week high+17.0%
$79.10Swing high (Oct 1)+1.2%
$78.96Pivot R1+1.0%
$78.20Last close
$77.63Pivot−0.7%
$76.86Pivot S1−1.7%
$74.4250 day average−4.8%
$73.85Swing low (Sep 25)−5.6%
$72.9620 day average−6.7%
$70.44100 day average−9.9%
$68.10200 day average−12.9%
$53.8952 week low−31.1%
Indicators
RSI (14)59.56Middle of its rangeNeutral
MACD1.32Above its signal lineBullish
Stochastic85.9Near the top of its rangeOverbought
ADX (14)17.8No clear trend
Williams %R-19.9Oversold below −80, overbought above −20Overbought
CCI (20)110.7Oversold below −100, overbought above 100Overbought
Rate of change+7.7%Change over 10 sessionsBullish
ATR (14)$3.68Typical daily range, 4.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for TARS

What happened before

See how TARS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow TARS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TARS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in TARS in the last 90 days.

Loading…

See today’s whale options flow across the market →

TARS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●142 buying vs 127 selling
  • ▲Held by funds +8.1 pts
  • ●Funds holding -1
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding256257−0.4%
In funds' top 1092+350.0%
Held by funds106.1%97.9%+8.1 pts
New / increased45 / 9737 / 103+1.4%
Reduced / sold out81 / 4684 / 34+7.6%
Put/call ratio0.0212.34−99.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TARS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TARS is in one of them and how their past TARS trades turned out.

TARS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TARS in an article yet. Here's the latest on the wider market.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals is a biopharmaceutical company based in Irvine, California, focused on developing and selling treatments for eye care. Its main product, XDEMVY, is an eye solution approved in the United States for Demodex blepharitis, an inflammation of the eyelids caused by mites. The company markets this product to eye care professionals and is developing other treatments, including candidates for ocular rosacea and for preventing Lyme disease.

Headquarters
Irvine, CA